Twist Bioscience reported fiscal Q1 revenue of $103.7 million, a 17% year‑on‑year increase, and credited growth to its DNA synthesis and protein solutions business and new AI‑enabled therapeutic discovery orders. CEO Emily Leproust highlighted $25 million in orders tied to AI‑driven discovery, and the company said it shipped a record number of synthetic genes during the quarter. Twist’s results underscore rising demand for outsourced DNA synthesis and contrast between therapeutic discovery and diagnostic markets. Management flagged expanding relationships with large pharma, biotech and technology firms entering life sciences, and the quarter included growth across therapeutics and NGS applications segments.